Fierce Pharma Asia

Asia
Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.
Angus Liu Sep 25, 2026 9:38am
Asia

US' China deal policy, WCLC, Legend CEO—Fierce Pharma Asia

Sep 18, 2026 10:20am
Asia

Takeda, Daiichi, Samsung Bio and more—Fierce Pharma Asia

Sep 11, 2026 9:15am
Asia

Roche, GSK, Novartis, MFN, Akeso and more—Fierce Pharma Asia

Sep 4, 2026 8:52am
Asia

Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia

Aug 28, 2026 9:00am
globe asia

China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia

Aug 21, 2026 9:00am